Company Description

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.

It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal Pharmaceuticals, Inc.

Country	United States
Founded	2011
Industry	Biotechnology
Sector	Healthcare
Employees	528
CEO	William Sibold

Contact Details

Address: Four Tower Bridge, Suite 200 West Conshohocken, Pennsylvania 19428 United States
Phone	267 824 2827
Website	madrigalpharma.com

Stock Details

Ticker Symbol	MDGL
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001157601
CUSIP Number	558868105
ISIN Number	US5588681057
SIC Code	2834

Key Executives

Name	Position
William J. Sibold	Chief Executive Officer, President and Director
Dr. Rebecca A. Taub M.D.	Founder, Senior Scientific and Medical Advisor and Director
Mardi C. Dier	Executive Vice President and Chief Financial Officer
Shannon Kelley	Executive Vice President, Chief Legal Officer and Corporate Secretary
Carole Huntsman	Executive Vice President and Chief Commercial Officer
Mark Underwood	Executive Vice President of Business Planning and Operations
Ronald Filippo	Executive Vice President and Chief Information Officer
Tina E. Ventura	Chief Investor Relations Officer
Clint Wallace	Executive Vice President and Chief Human Resources Officer
Edward Chiang	Senior Vice President of Clinical and Technical Operations

Latest SEC Filings

Date	Type	Title
Sep 11, 2025	S-8	Securities to be offered to employees in employee benefit plans
Sep 9, 2025	144	Filing
Aug 29, 2025	144	Filing
Aug 21, 2025	144	Filing
Aug 20, 2025	144	Filing
Aug 18, 2025	144	Filing
Aug 18, 2025	144	Filing
Aug 15, 2025	144	Filing
Aug 15, 2025	144	Filing
Aug 14, 2025	SCHEDULE 13G/A	Filing

View All SEC Filings